| 2026-01-13 | +115.3% | M&A | Quiver Quantitative | Beyond Air Stock (XAIR) Opinions on NeuroNOS Acquisition Deal | XAIR Stock News - Quiver Quantitative |
| 2026-01-13 | +115.3% | M&A | Stock Titan | Two Nobel laureates back new autism drug effort in XTL’s NeuroNOS deal - Stock Titan |
| 2026-01-13 | +115.3% | news | TipRanks | Why Is Beyond Air Stock (XAIR) Up Today? - TipRanks |
| 2026-01-13 | +115.3% | news | Stocktwits | XAIR Stock More Than Doubled Today — What’s Driving The Rally? - Stocktwits |
| 2026-01-13 | +115.3% | executive | StocksToTrade | Beyond Air Expands Globally with LungFit PH; Executes Key CFO Appointment - StocksToTrade |
| 2026-01-13 | +115.3% | news | ChartMill | These stocks that are showing activity before the opening bell on Tuesday. - ChartMill |
| 2026-01-13 | +115.3% | M&A | Benzinga | Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments - Benzinga |
| 2024-06-25 | -53.2% | news | InvestorPlace | Why Is Beyond Air (XAIR) Stock Down 22% Today? - InvestorPlace |
| 2024-06-24 | -47.7% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript |
| 2022-07-05 | +33.7% | legal | SEC EDGAR | XAIR 8-K: 5.02 and (SEC Filing) |
| 2025-09-09 | -32.2% | legal | SEC EDGAR | XAIR 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2024-10-02 | +27.3% | legal | SEC EDGAR | XAIR 8-K: 1.01, 2.03and3.02 (SEC Filing) |
| 2025-08-13 | -26.9% | earnings | Yahoo Finance | Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... - Yahoo Finance |
| 2025-08-12 | -23.9% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript |
| 2025-08-12 | -23.9% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$1.53 misses by $0.21, revenue of $1.76M beats by $0.01M |
| 2026-04-15 | -23.0% | news | GlobeNewswire | Beyond Air to Participate in the D. Boral Capital Global Conference 2026 |
| 2026-04-15 | -23.0% | legal | SEC EDGAR | XAIR 8-K: 8.01 (SEC Filing) |
| 2026-04-15 | -23.0% | executive | Stock Titan | Beyond Air CEO, CFO set one-on-one investor meetings in New York - Stock Titan |
| 2026-04-15 | -23.0% | news | Stock Titan | Beyond Air (NASDAQ: XAIR) appeals Nasdaq $1 bid-price noncompliance in May hearing - Stock Titan |
| 2026-04-15 | -23.0% | news | TipRanks | Beyond Air Appeals Nasdaq Notice on Listing Compliance - TipRanks |
| 2026-04-10 | -22.9% | news | TipRanks | Beyond Air Faces Nasdaq Delisting Risk After Bid-Price Breach - TipRanks |
| 2026-04-10 | -22.9% | news | Stock Titan | Nasdaq warns Beyond Air (NASDAQ: XAIR) on sub-$1 bid price and listing risk - Stock Titan |
| 2026-01-14 | -21.2% | news | Stock Titan | Beyond Air raises $5M in stock-and-warrant sale to institutional buyer - Stock Titan |
| 2026-01-14 | -21.2% | news | StocksToTrade | XAIR Stock Soars Amid Strategic Market Moves and Financial Adjustments - StocksToTrade |
| 2026-01-14 | -21.2% | news | timothysykes.com | Title: Beyond Air Inc. Navigates Market Dynamics Amid Strategic Announcements - timothysykes.com |
| 2026-01-14 | -21.2% | news | CoinCentral | Beyond Air (XAIR) Stock Soars 150% on $32M NeuroNOS Subsidiary Sale - CoinCentral |
| 2026-01-14 | -21.2% | news | The Manila Times | Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - The Manila Times |
| 2026-01-14 | -21.2% | news | Blockonomi | Beyond Air (XAIR) Stock Soars as Company Sells Autism Drug Platform for $32.5 Million - Blockonomi |
| 2023-06-23 | -19.8% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | -18.8% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript |
| 2025-11-10 | -18.8% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$1.25 misses by $0.46, revenue of $1.82M misses by $0.72M |
| 2025-11-10 | -18.8% | earnings | ChartMill | Beyond Air Inc (NASDAQ:XAIR) Stock Falls 11.5% After Q2 2026 Earnings Miss - ChartMill |
| 2022-06-30 | +18.5% | legal | SEC EDGAR | XAIR 8-K: 2.02, 8.01 (SEC Filing) |
| 2024-01-29 | +18.2% | analyst | TradingView | XAIR Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-06-18 | -18.1% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript |
| 2025-06-18 | -18.1% | legal | SEC EDGAR | XAIR 8-K: 2.02, 5.02, 8.01 (SEC Filing) |
| 2026-01-26 | -17.6% | news | Stock Titan | Beyond Air to detail third-quarter results in Feb. 13 call - Stock Titan |
| 2026-01-26 | -17.6% | earnings | Quiver Quantitative | Beyond Air, Inc. to Report Q3 Fiscal 2025 Financial Results on February 13, 2026 - Quiver Quantitative |
| 2025-07-10 | -17.5% | news | Investing.com | Beyond Air to implement 1-for-20 reverse stock split effective July 14 - Investing.com |
| 2025-03-14 | +17.5% | legal | SEC EDGAR | XAIR 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-06-29 | +16.6% | legal | InvestorPlace | Beyond Air (XAIR) Stock Gains Almost 20% on FDA Approval - InvestorPlace |
| 2025-11-11 | -16.1% | analyst | GuruFocus | Beyond Air (XAIR) Receives Reaffirmed Buy Rating from D. Boral C - GuruFocus |
| 2024-08-06 | -15.3% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$0.27 beats by $0.05, revenue of $0.68M misses by $0.12M |
| 2025-02-11 | -15.3% | earnings | Seeking Alpha | Beyond Air projects sequential revenue growth with expanded LungFit PH adoption |
| 2025-02-11 | -15.3% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript |
| 2024-06-27 | -15.1% | legal | SEC EDGAR | XAIR 8-K: 1.01, 2.02, 2.03 (SEC Filing) |
| 2021-08-25 | +14.8% | legal | SEC EDGAR | XAIR 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-09-08 | +14.5% | legal | Seeking Alpha | Beyond Air secures $3.25M via warrant exercise and new issuance |
| 2025-09-08 | +14.5% | legal | Stock Titan | Breakthrough for Deadliest Brain Cancer: NeuroNOS's BA-101 Gets FDA Orphan Status for Glioblastoma Treatment - Stock Titan |
| 2025-09-08 | +14.5% | news | StocksToTrade | Beyond Air’s Rise: Fluke or Everlasting? - StocksToTrade |
| 2023-08-15 | -14.1% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2026-01-27 | -13.4% | executive | Stock Titan | Beyond Air CEO lines up two investor conference appearances - Stock Titan |
| 2025-06-17 | +13.1% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$0.09 beats by $0.03, revenue of $1.15M misses by $0.24M |
| 2023-03-13 | +12.0% | legal | SEC EDGAR | XAIR 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-08-23 | +11.8% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2024-11-06 | +11.1% | legal | SEC EDGAR | XAIR 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2026-01-21 | -10.9% | analyst | GuruFocus | Beyond Air (XAIR) Analyst Rating Maintained as Buy at $11.00 by D. Boral Capital | XAIR Stock News - GuruFocus |
| 2025-11-28 | -10.6% | legal | SEC EDGAR | XAIR 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-08-20 | -10.1% | legal | Seeking Alpha | Beyond Air files 1.7M secondary stock offering |
| 2025-06-26 | -9.9% | news | Yahoo Finance | Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher - Yahoo Finance |
| 2026-01-15 | -9.8% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2026-01-15 | -9.8% | news | Finimize | Beyond Air’s Nitric Oxide Bet Faces Cash Burn And Dilution - Finimize |
| 2021-11-15 | +9.4% | legal | SEC EDGAR | XAIR 8-K: 1.02, 2.02 (SEC Filing) |
| 2023-03-23 | -9.0% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2024-10-25 | +8.1% | news | Seeking Alpha | Beyond Air files to sell 81.7M shares of common stock for holders |
| 2026-01-20 | +8.0% | legal | SEC EDGAR | XAIR 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-05-12 | -7.6% | news | Intellectia AI | XAIR Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2026-02-04 | -7.4% | news | Stock Titan | Ultra-high nitric oxide cancer immunotherapy data heads to AACR 2026 - Stock Titan |
| 2025-03-24 | +7.3% | analyst | Quiver Quantitative | XAIR | Beyond Air, Inc. Common Analyst Forecasts - Quiver Quantitative |
| 2025-11-05 | -6.3% | legal | SEC EDGAR | XAIR 8-K: 1.01, 2.03, 3.02, 5.02, 8.01 (SEC Filing) |
| 2026-03-10 | -6.2% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th |
| 2026-03-10 | -6.2% | news | Seeking Alpha | Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals |
| 2024-03-22 | +6.0% | legal | SEC EDGAR | XAIR 8-K: 1.01, 8.01 (SEC Filing) |
| 2022-10-20 | +5.8% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | -5.8% | news | ChartMill | XAIR Stock Price, Quote & Chart | BEYOND AIR INC (NASDAQ:XAIR) - ChartMill |
| 2026-04-23 | -5.8% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Beyond Air (XAIR) Market Position | Q1 2026: Profit Surprises - Open Stock Signal Network - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-02-13 | +5.7% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript |
| 2026-02-13 | +5.7% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$0.85 misses by $0.03, revenue of $2.2M beats by $0.05M |
| 2026-02-13 | +5.7% | legal | SEC EDGAR | XAIR 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-13 | +5.7% | earnings | ChartMill | BEYOND AIR INC (NASDAQ:XAIR) Posts Revenue Beat, Reaffirms Guidance in Q3 2026 - ChartMill |
| 2026-02-13 | +5.7% | earnings | The Globe and Mail | Beyond Air XAIR Q3 2026 Earnings Call Transcript - The Globe and Mail |
| 2025-11-14 | -5.3% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2024-11-12 | -5.0% | earnings | Seeking Alpha | Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript |
| 2021-05-13 | -4.5% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2026-04-20 | -4.5% | news | GlobeNewswire | Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 |
| 2026-04-20 | -4.5% | news | GuruFocus | Beyond Air (XAIR) Reports Promising Data from Phase 1 Clinical T - GuruFocus |
| 2026-04-20 | -4.5% | news | Stock Titan | After UNO tumor injection, 6 of 10 heavily treated patients remain alive - Stock Titan |
| 2025-08-11 | +4.5% | earnings | Yahoo Finance | Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect - Yahoo Finance |
| 2024-11-11 | +4.4% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$0.28 in-line, revenue of $0.79M misses by $0.24M |
| 2022-08-15 | -4.4% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2024-03-01 | -4.2% | legal | SEC EDGAR | XAIR 8-K: 1.01 and (SEC Filing) |
| 2022-11-22 | -4.1% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Beyond Air (XAIR) - Zacks Investment Research |
| 2025-01-31 | -4.1% | legal | Seeking Alpha | Beyond Air files for $200M mixed securities shelf |
| 2024-11-18 | +4.0% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2024-02-12 | -3.9% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-12-30 | +3.8% | executive | Seeking Alpha | Beyond Air appoints Dan Moorhead as CFO |
| 2025-12-30 | +3.8% | legal | SEC EDGAR | XAIR 8-K: 1.01, 5.02, 8.01 (SEC Filing) |
| 2025-12-30 | +3.8% | executive | Quiver Quantitative | Beyond Air, Inc. Appoints Dan Moorhead as Chief Financial Officer | XAIR Stock News - Quiver Quantitative |
| 2025-12-30 | +3.8% | expansion | Stock Titan | New finance chief joins nitric oxide device maker before LungFit PH launch - Stock Titan |
| 2025-03-23 | +3.8% | analyst | Yahoo Finance | Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts - Yahoo Finance |
| 2024-03-14 | -3.7% | legal | SEC EDGAR | XAIR 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-02-14 | +3.7% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2025-12-11 | -3.7% | legal | SEC EDGAR | XAIR 8-K: 5.02 and (SEC Filing) |
| 2022-02-04 | +3.5% | legal | SEC EDGAR | XAIR 8-K: 1.01 and (SEC Filing) |
| 2024-11-26 | +3.4% | legal | SEC EDGAR | XAIR 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2021-11-05 | -3.4% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2021-09-27 | -3.2% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2024-12-17 | -3.1% | news | Investing.com | Beyond Air's SWOT analysis: LungFit PH maker faces cash burn as stock seeks lift - Investing.com |
| 2024-08-05 | -3.1% | earnings | Seeking Alpha | Beyond Air Q1 Earnings Preview |
| 2021-08-11 | -3.0% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2021-10-20 | +2.9% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2023-03-24 | -2.9% | legal | SEC EDGAR | XAIR 8-K: 8.01 (SEC Filing) |
| 2025-11-09 | -2.7% | earnings | Seeking Alpha | Beyond Air Q2 2026 Earnings Preview |
| 2026-03-04 | -2.6% | news | Yahoo Finance | Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies - Yahoo Finance |
| 2022-03-04 | +2.6% | legal | SEC EDGAR | XAIR 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-04-24 | +2.5% | news | Seeking Alpha | Beyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric Oxide |
| 2025-04-24 | +2.5% | news | Stock Titan | XAIR Stock Price, News & Analysis | Beyond Air - Stock Titan |
| 2025-02-14 | -2.4% | legal | SEC EDGAR | XAIR 8-K: 1.01 and (SEC Filing) |
| 2025-02-14 | -2.4% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | +2.4% | earnings | Seeking Alpha | Beyond Air Q3 2026 Earnings Preview |
| 2025-02-10 | -2.2% | earnings | Seeking Alpha | Beyond Air GAAP EPS of -$0.15 beats by $0.01, revenue of $1.07M beats by $0.14M |
| 2024-08-09 | +2.1% | legal | SEC EDGAR | XAIR 8-K: 2.02, 3.01, 5.02 (SEC Filing) |
| 2024-09-27 | +2.1% | news | Seeking Alpha | Beyond Air announces $20.6M private equity offering |
| 2024-09-27 | +2.1% | legal | SEC EDGAR | XAIR 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-04-01 | +2.1% | expansion | GlobeNewswire | Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) |
| 2026-04-01 | +2.1% | legal | SEC EDGAR | XAIR 8-K: 1.01, 5.02, 7.01 (SEC Filing) |
| 2026-04-01 | +2.1% | news | Stock Titan | Nearly 2,000 more hospitals can buy Beyond Air's tankless nitric oxide system - Stock Titan |
| 2026-04-01 | +2.1% | news | Stock Titan | [8-K] Beyond Air, Inc. Reports Material Event - Stock Titan |
| 2024-12-03 | -2.0% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2026-03-13 | +2.0% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing |
| 2024-02-16 | -1.9% | legal | SEC EDGAR | XAIR 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-02-05 | +1.8% | news | Seeking Alpha | Beyond Air granted 180-day extension to regain Nasdaq compliance |
| 2025-02-05 | +1.8% | news | Stock Titan | Beyond Air Battles Nasdaq Delisting: Crucial Extension Granted as Clock Ticks - Stock Titan |
| 2026-03-17 | -1.6% | news | MT Newswires | Beyond Air Unit Reports Positive Safety Data From Phase 1 Intratumoral Nitric Oxide Monotherapy |
| 2026-03-17 | -1.6% | news | GlobeNewswire | Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial |
| 2026-03-17 | -1.6% | news | Stock Titan | High-dose nitric oxide shot shows early activity in small cancer trial - Stock Titan |
| 2025-03-28 | -1.5% | legal | SEC EDGAR | XAIR 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-03-18 | -1.5% | analyst | GuruFocus | Beyond Air (XAIR) Retains 'Buy' Rating with $10 PT by D. Boral C - GuruFocus |
| 2026-04-21 | -1.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Beyond Air (XAIR) Stock: Trend Strength (Touches High) 2026-04-20 - Hot Community Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-02 | -1.3% | legal | Stock Titan | XAIR SEC Filings - Beyond Air Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-03-26 | +1.0% | executive | MT Newswires | Beyond Air CEO Steve Lisi Resigns; COO to Succeed |
| 2026-03-26 | +1.0% | executive | GlobeNewswire | Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO |
| 2026-03-26 | +1.0% | executive | Seeking Alpha | Beyond Air CEO Steve Lisi resigns, Robert Goodman appointed successor |
| 2026-03-26 | +1.0% | executive | Stock Titan | Beyond Air swaps CEOs as it pushes wider LungFit PH rollout - Stock Titan |
| 2026-03-26 | +1.0% | executive | Investing.com | Beyond Air stock sees CEO change as BTIG maintains Neutral rating - Investing.com |
| 2024-12-06 | +0.9% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2023-06-20 | -0.8% | legal | SEC EDGAR | XAIR 8-K: 1.01, 2.03, 8.01 (SEC Filing) |
| 2021-05-26 | +0.8% | legal | SEC EDGAR | XAIR 8-K: 1.01 (SEC Filing) |
| 2025-08-18 | -0.7% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2021-08-19 | +0.7% | earnings | Zacks Investment Research | What date does Beyond Air's (XAIR) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-04-06 | -0.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Beyond Air (XAIR) Stock in a Selling Zone | Price at $0.73, Up 2.87% - Trending Social Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-11-26 | -0.5% | executive | Seeking Alpha | Beyond Air appoints Duke Drewell as interim CFO |
| 2023-09-07 | -0.5% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2021-06-16 | -0.3% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2025-05-28 | +0.2% | news | Intellectia AI | XAIR Forecast — Price Prediction for 2026. Should I Buy XAIR? - Intellectia AI |
| 2023-02-13 | +0.2% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | -0.2% | news | GlobeNewswire | Beyond Air to Participate in the 38th Annual Roth Conference in March |
| 2025-09-25 | -0.1% | news | Seeking Alpha | Beyond Air registers 719,561 shares for potential resale by warrant holders |
| 2021-12-10 | +0.1% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2023-11-17 | +0.1% | legal | SEC EDGAR | XAIR 8-K: 2.02 and (SEC Filing) |
| 2024-06-18 | +0.0% | legal | SEC EDGAR | XAIR 8-K: 8.01 and (SEC Filing) |
| 2022-11-14 | +0.0% | legal | SEC EDGAR | XAIR 8-K: 2.02, 8.01 (SEC Filing) |
| 2026-04-24 | — | news | Stock Titan | Beyond Air (NASDAQ: XAIR) seeks approval for 1-for-2 to 1-for-20 reverse split to address $1 bid rule - Stock Titan |